Business Description
BioArctic AB
SIC : 2834
ISIN : SE0010323311
Share Class Description:
LTS:0RV2: Class BTotal Employee Number:
141Compare
Compare
Traded in other countries / regions
BIOA B.Sweden0RV2.UKBRCTF.USAB9A.Germany IPO Date
2017-10-18Description
BioArctic AB is a Swedish research-based biopharmaceutical company that develops disease-modifying treatments and diagnostics for neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and ALS. Its pipeline is built on proprietary technologies such as BrainTransporter, a platform for enhancing antibody transport across the blood-brain barrier, and its lead asset lecanemab (marketed as Leqembi), an Alzheimer's antibody developed with Eisai, which holds global commercialization rights. BioArctic also has collaborations with partners including AbbVie and Eisai, generating revenue through licensing fees, milestone payments, and royalties on partnered products. The company is headquartered in Stockholm, Sweden, and its shares are listed on Nasdaq Stockholm. Its revenue is largely derived from partnership milestones and royalties rather than direct product sales, with North America representing a significant share of that revenue.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 21.96 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.35 | |||||
Interest Coverage | 22.93 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 22.71 | |||||
Beneish M-Score | -3.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 106.1 | |||||
3-Year EBITDA Growth Rate | 582.7 | |||||
3-Year Book Growth Rate | 35.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.9 | |||||
9-Day RSI | 45.91 | |||||
14-Day RSI | 47.64 | |||||
3-1 Month Momentum % | 10.28 | |||||
6-1 Month Momentum % | 6.73 | |||||
12-1 Month Momentum % | 18.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.99 | |||||
Quick Ratio | 3.99 | |||||
Cash Ratio | 2.97 | |||||
Days Sales Outstanding | 44.29 | |||||
Days Payable | 127.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.62 | |||||
Dividend Payout Ratio | 1.69 | |||||
Forward Dividend Yield % | 0.62 | |||||
5-Year Yield-on-Cost % | 0.62 | |||||
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 0.62 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.17 | |||||
Operating Margin % | 20.83 | |||||
Net Margin % | 10.53 | |||||
EBITDA Margin % | 25.71 | |||||
FCF Margin % | 24.34 | |||||
OCF Margin % | 24.34 | |||||
ROE % | 5.18 | |||||
ROA % | 4.06 | |||||
ROIC % | 14.51 | |||||
3-Year ROIIC % | 310.33 | |||||
ROC (Joel Greenblatt) % | 160.04 | |||||
ROCE % | 12.21 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 272.87 | |||||
Forward PE Ratio | 104.7 | |||||
PE Ratio without NRI | 272.87 | |||||
Shiller PE Ratio | 160.78 | |||||
Price-to-Owner-Earnings | 23.69 | |||||
PS Ratio | 28.51 | |||||
PB Ratio | 14.16 | |||||
Price-to-Tangible-Book | 14.08 | |||||
Price-to-Free-Cash-Flow | 116.83 | |||||
Price-to-Operating-Cash-Flow | 116.83 | |||||
EV-to-EBIT | 103.17 | |||||
EV-to-Forward-EBIT | 12.49 | |||||
EV-to-EBITDA | 103.17 | |||||
EV-to-Forward-EBITDA | 66.86 | |||||
EV-to-Revenue | 26.51 | |||||
EV-to-Forward-Revenue | 24.71 | |||||
EV-to-FCF | 108.47 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Projected-FCF | 6.47 | |||||
Price-to-Graham-Number | 13.04 | |||||
| Price-to-Net-Current-Asset-Value | 15.16 | |||||
| Price-to-Net-Cash | 23.93 | |||||
Earnings Yield (Greenblatt) % | 0.97 | |||||
FCF Yield % | 0.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioArctic AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 1,002.491 | ||
| EPS (TTM) (kr) | 1.184 | ||
| Beta | 1.2801 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | 10.71 | ||
| 14-Day RSI | 47.64 | ||
| 14-Day ATR (kr) | 325.832558 | ||
| 20-Day SMA (kr) | 328.18 | ||
| 12-1 Month Momentum % | 18.21 | ||
| 52-Week Range (kr) | 258.8 - 364.4 | ||
| Shares Outstanding (Mil) | 88.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioArctic AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioArctic AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-18 09:30 | In 150 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-18 08:00 | In 150 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-18 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-11-18 | In 57 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-26 03:30 | 341.20 (+2.22%) | ||
| Second quarter earnings results for 2026 | 2026-08-26 | 341.20 (+2.22%) | ||
| SEK 2.000000 Cash Dividend | 2026-05-29 | 337.80 (+0.12%) | ||
| General meeting for 2026 | 2026-05-28 16:30 | 336.80 (-0.18%) | ||
| First quarter earnings conference call for 2026 | 2026-05-20 09:30 | 310.70 (-1.46%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 310.70 (-1.46%) |
Show
Entries
BioArctic AB Frequently Asked Questions
What is BioArctic AB(LTS:0RV2)'s stock price today?
The current price of LTS:0RV2 is kr322.10. The 52 week high of LTS:0RV2 is kr364.40 and 52 week low is kr258.80.
When is next earnings date of BioArctic AB(LTS:0RV2)?
The next earnings date of BioArctic AB(LTS:0RV2) is 2026-11-18.
Does BioArctic AB(LTS:0RV2) pay dividends? If so, how much?
The Dividend Yield %  of BioArctic AB(LTS:0RV2) is 0.62% (As of Today), Highest Dividend Payout Ratio of BioArctic AB(LTS:0RV2) was 1.69. The lowest was 1.5. And the median was 1.5. The  Forward Dividend Yield % of BioArctic AB(LTS:0RV2) is 0.62%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers